Skip to main content

Table 2 Prevalence and incidence of individual HPV types among HIV-negative and HIV-positive adolescent women participating in the REACH study during the before and after HAART initiation period

From: The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents

  ALL Participants Case-crossover with Both Before and After HAART Initiation
  Prevalence [95% CI] (%) Incidence [95% CI] (cases/100 person-years) Prevalence [95% CI] (%) Incidence [95% CI] (cases/100 person-years)
HPV Types HIV- n = 146 HIV+Before HAART n = 170 HIV+After HAART n = 157 HIV- n = 146 HIV+Before HAART n = 170 HIV+After HAART n = 157 Before HAART n = 100 After HAART n = 100 Before HAART n = 100 After HAART n = 100
Carcinogenic           
HPV 16a, c 6 (2-10) 17 (11-22)*** 10(5-14) 6.83
(3.53-11.96)
6.54
(3.38-11.45)
6.67
(3.45-11.68)
20 (12-28)§§ 7 (2-12) 4.12
(2.13-7.20)
4.64
(2.40-8.12)
HPV18a, c 8 (3-12) 8 (4-12) 6(2-9) 4.66
(2.41-8.15)
6.27
(3.24-10.97)
7.32
(3.78-12.81)
10 (4-16) 4 (0-8) 8.49
(4.39-14.86)
5.72
(2.96-10.02)
HPV39a 0.7 (0-2) 4(1-7)* 4 (1-8)# 1.93
(0.99-3.37)
3.00
(1.55-5.25)
3.06
(1.58-5.36)
7 (2-12) 3 (0-6) 4.73
(2.45-8.28)
1.50
(0.78-2.63)
HPV45a 2 (0-6) 5 (2-8) 4 (1-8) 3.92
(2.02-6.85)
4.30
(2.23-7.53)
4.66
(2.41-8.16)
5 (1-9) 5 (1-9) 4.55
(2.35-7.97)
3.91
(2.02-6.84)
HPV51a 3 (0-6) 2 (0-5) 3 (0-5) 4.86
(2.51-8.51)
4.67
(2.41-8.17)
4.48
(2.31-7.83)
1 (0-3) 2 (0-5) 4.42
(2.29-7.74)
3.68
(1.90-6.45)
HPV52a 3 (0-5) 10 (5-15) 9 (4-13)# 4.67
(2.41-8.17)
5.02
(2.59-8.78)
5.11
(2.64-8.95)
12 (6-18)§ 4 (0-8) 7.26
(3.76-12.71)
3.17
(1.64-5.55)
HPV56a 2 (0-4) 8 (4-12)* 4 (1-7) 2.60
(1.34-4.56)
5.44
(2.81-9.53)
4.21
(2.18-7.37)
8 (3-13)§ 1 (0-3) 7.14
(3.69-12.49)
5.98
(3.09-10.47)
HPV58a 10 (5-14) 16 (11-22) 10 (5-15) 7.36
(3.80-12.88)
7.71
(3.99-13.49)
7.04
(3.64-12.32)
20 (12-28)§§§ 6 (1-11) 6.93
(3.58-12.13)
5.93
(3.07-10.38)
HPV67b 0.7 (0-2) 1 (0-2) 1 (0-2) 0.64*
(0.33-1.13)
3.75
(1.94-6.56)
1.49
(0.77-2.61)
1 (0-3) 0 3.29
(1.70-5.75)
1.46
(0.76-2.56)
HPV26/69b 2(0-4) 1 (0-3) 3 (0-6) 2.62*
(1.35-4.58)
6.79
(3.51-11.88)
3.43
(1.78-6.01)
0 2 (0-5) 6.60
(3.41-11.55)
5.96
(3.08-10.42)
HPV53/66b 5 (2-9) 12 (7-17)* 18 (12-24)### 9.83
(5.08-17.20)
12.80
(6.62-22.39)
17.05#
(8.82-29.84)
11 (5-17) 12 (6-18) 12.93
(6.68-22.62)
19.49
(10.08-34.10)
HPV68/70b 5 (2-9) 11 (5-15) 13 (8-19)# 7.91
(4.09-13.85)
9.01
(4.66-15.77)
11.30
(5.84-19.77)
15 (8-22) 12 (6-18) 10.36
(5.35-18.12)
12.18
(6.30-21.31)
HPV31/33/35a 8 (4-13) 14 (8-19) 10 (5-15) 6.87
(3.55-12.03)
7.52
(3.89-13.15)
8.85
(4.58-15.49)
13 (6-20) 6 (1-11) 6.34
(3.28-11.10)
7.77
(4.02-13.59)
Low Risk           
HPV6/11/42/44c, d 8 (4-13) 14 (8-19) 8 (4-13) 5.30
(2.74-9.27)
7.97
(4.12-13.95)
8.76
(4.53-15.32)
20 (12-28)§ 8 (3-13) 7.59
(3.93-13.29)
8.41
(4.35-14.72)
HPV54/40d 3(0-5) 3 (0-5) 3 (0-6) 5.89 (3.04-10.31) 8.49
(4.39-14.85)
8.01
(4.14-14.02)
4 (0-8) 1 (0-3) 6.67
(3.45-11.68)
11.11
(5.74-19.44)
HPV13/32d 0.7 (0-2) 1 (0-2) 3 (0-5) 2.24
(1.16-3.92)
4.59
(2.37-8.03)
3.71
(1.92-6.50)
1 (0-3) 3 (0-6) 2.20
(1.14-3.85)
5.14
(2.66-8.99)
HPV62/72d 0.7 (0-2) 1 (0-2) 1 (0-3) 1.60
(0.83-2.80)
2.91
(1.51-5.10)
5.18#
(2.68-9.06)
0 0 1.09§
(0.56-1.91)
7.20
(3.72-12.60)
HPV2/57d 0 1 (0-2) 0 0 0.83
(0.43-1.46)
1.45#
(0.75-2.55)
1 (0-3) 0 0 1.43
(0.74-2.50)
HPV55d 0 0 0 0.96
(0.50-1.68)
1.66
(0.86-2.91)
0.36
(0.19-0.64)
0 0 0 0.71
(0.37-1.25)
  1. a high risk, b probably/possibly carcinogenic, c vaccine type, and d low-risk HPV type; * 0.01 > p > 0.05, **0.05 > p > 0.005, ***0.005 > p - HIV+ before HAART initiation vs hiv-; # 0.01 > p > 0.05, ##0.05 > p > 0.005, ###0.005 > p -HIV+ after HAART initiation vs hiv-; +0.01 > p > 0.05, ++0.05 > p > 0.005, +++0.005 > p - before vs. after HAART initiation; §0.01 > p > 0.05, §§0.05 > p > 0.005, §§§0.005 > p - before vs. after HAART initiation (with both follow-up).